AIM Net Income Per Share from 2010 to 2026

AIM Stock  USD 1.14  0.09  7.32%   
AIM ImmunoTech Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to -29.22. During the period from 2010 to 2026, AIM ImmunoTech Net Loss quarterly data regression pattern had range of 6.5 K and standard deviation of  2,346. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(27.83)
Current Value
(29.22)
Quarterly Volatility
2.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check AIM ImmunoTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AIM ImmunoTech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 210.3 K, Total Revenue of 145.3 K or Gross Profit of 131.4 K, as well as many indicators such as Price To Sales Ratio of 72.0, Dividend Yield of 0.0 or Days Sales Outstanding of 2 K. AIM financial statements analysis is a perfect complement when working with AIM ImmunoTech Valuation or Volatility modules.
  
Build AI portfolio with AIM Stock
Check out the analysis of AIM ImmunoTech Correlation against competitors.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
Evaluating AIM ImmunoTech's Net Income Per Share across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into AIM ImmunoTech's fundamental strength.

Latest AIM ImmunoTech's Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of AIM ImmunoTech over the last few years. It is AIM ImmunoTech's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AIM ImmunoTech's overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

AIM Net Income Per Share Regression Statistics

Arithmetic Mean(1,966)
Coefficient Of Variation(119.33)
Mean Deviation2,040
Median(977.10)
Standard Deviation2,346
Sample Variance5.5M
Range6.5K
R-Value0.88
Mean Square Error1.3M
R-Squared0.78
Slope410.24
Total Sum of Squares88.1M

AIM Net Income Per Share History

2026 -29.22
2025 -27.83
2024 -30.92
2023 -59.61
2022 -40.47
2021 -40.4
2020 -45.22

About AIM ImmunoTech Financial Statements

AIM ImmunoTech investors utilize fundamental indicators, such as Net Income Per Share, to predict how AIM Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss(27.83)(29.22)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports:
Check out the analysis of AIM ImmunoTech Correlation against competitors.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Will Biotechnology sector continue expanding? Could AIM diversify its offerings? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AIM ImmunoTech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(18.16)
Revenue Per Share
0.106
Quarterly Revenue Growth
(0.26)
Return On Assets
(0.95)
Return On Equity
(31.39)
AIM ImmunoTech's market price often diverges from its book value, the accounting figure shown on AIM's balance sheet. Smart investors calculate AIM ImmunoTech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since AIM ImmunoTech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that AIM ImmunoTech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AIM ImmunoTech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.